A persistent challenge in anti-cancer drug development remains translation from animal studies to human clinical trials. A shocking 57% of late-stage oncology trials fail due to inadequate efficacy. These failures amount to billions of dollars in...

On December 15th, 2020, Dr. Jonathan Nakashima, PhD, CSO of Certis Oncology, joined Taconic Biosciences to present a comprehensive overview of O-PDX testing. O-PDX is a technique which uses in vivo pharmacology testing in personalized mouse models,...